^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AiRuiLi (adebrelimab)

    i
    Other names: SHR-1316, SHR 1316, HTI-1088, HTI-1316, HTI1088, HTI 1088, HTI 1316, HTI1316, SHR1316
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1d
    Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Tang-Du Hospital
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
    4d
    A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
    P3, N=462, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • gemcitabine • SHR-A2102 • AiRuiLi (adebrelimab)
    7d
    Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC. (clinicaltrials.gov)
    P2, N=60, Recruiting, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2025 --> Jun 2026
    Enrollment open • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    carboplatin • albumin-bound paclitaxel • oxaliplatin • AiRuiLi (adebrelimab)
    7d
    Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study (clinicaltrials.gov)
    P2, N=42, Recruiting, The Affiliated Hospital of Putian University
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
    9d
    A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC (clinicaltrials.gov)
    P=N/A, N=500, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New trial • Real-world evidence
    |
    AiRuiLi (adebrelimab)
    10d
    Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=25, Recruiting, The Second Hospital of Shandong University
    New trial
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
    12d
    Adebrelimab in combination with dalpiciclib and endocrine therapy as neoadjuvant treatment for HR+/HER2- early breast cancer: an exploratory study. (PubMed, Int J Surg)
    This triplet regimen demonstrated modest clinical activity in HR+/HER2- early BC, with the safety profile of this regimen remains a concern and warrants particular attention in clinical practice.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    letrozole • AiRuiKang (dalpiciclib) • AiRuiLi (adebrelimab)
    22d
    SHR-A1811-Ib/II-205: Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer (clinicaltrials.gov)
    P2, N=258, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Active, not recruiting --> Recruiting | N=76 --> 258 | Trial completion date: Jul 2026 --> Dec 2027 | Trial primary completion date: Apr 2025 --> Dec 2027
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    5-fluorouracil • capecitabine • oxaliplatin • trastuzumab rezetecan (SHR-A1811) • retlirafusp alfa (SHR-1701) • AiRuiLi (adebrelimab)
    23d
    Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC) (clinicaltrials.gov)
    P2, N=60, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AiRuiLi (adebrelimab)
    24d
    Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, The Third Affiliated Hospital of Harbin Medical University
    New P2 trial
    |
    etoposide oral • AiRuiLi (adebrelimab)
    25d
    Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P2, N=202, Recruiting, Sichuan University | Not yet recruiting --> Recruiting | Phase classification: P3 --> P2
    Enrollment open • Phase classification
    |
    AiRuiLi (adebrelimab)
    28d
    A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
    P3, N=462, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • gemcitabine • SHR-A2102 • AiRuiLi (adebrelimab)